AI drug discovery company

Variational AI

Data as of Oct 17, 2026.

Company facts

Founded

2019

ConfirmedSource for founded (opens in new tab)
Headquarters

Canada (Vancouver)

ConfirmedSource for headquarters (opens in new tab)

Latest funding round

Round: Seed extension
Date: Feb 2025
Amount: $5.5M
Lead investor: Nimbus Synergies

ConfirmedSource for the latest round (opens in new tab)

Drug discovery partners

1 pharma, 1 other. Pharma here means a company with approved products and roughly $1B or more in annual revenue.

Merck & Co. Pharma

Discovery collaboration, Sep 23, 2025

$349M total potential (upfront not disclosed)

ConfirmedSource for Merck & Co. (opens in new tab)
Oncocross AI biotech

Atopic dermatitis AI partnership, Jun 19, 2025

Terms not disclosed

ConfirmedSource for Oncocross (opens in new tab)

Recent news

Sep 10, 2026

PRMT6 inhibitor discovery poster via AI-driven design

ConfirmedSource (opens in new tab)
Jun 11, 2026

Finalist in two categories of the 2026 BC Tech Technology Impact Awards

ConfirmedSource (opens in new tab)
Sep 23, 2025

Collaboration with Merck & Co. (MSD) applying Enki platform (official)

ConfirmedSource (opens in new tab)
Jun 19, 2025

AI partnership with Oncocross in atopic dermatitis

ConfirmedSource (opens in new tab)
Feb 2025

Seed extension: $5.5M

ConfirmedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.